VISION & MISSION

24 June, 2025

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Nanexa announces that the poster titled “A Single Ascending Dose Study of a Once-monthly Liraglutide Formulation in Participants with Type 2 Diabetes” was presented by the renowned diabetes researcher Dr. Hans de Vries, on Sunday, June 22, at the American Diabetes Association’s 85th Scientific Sessions. The poster, which presented all data, including the 30 mg NEX-22 dose cohort, was very well received, and there has been significant interest in the first published clinical data with a once-montly long-acting injection of a GLP-1 drug. A 30 mg dose of NEX-22 shows exposure for up to 36 days without significant gastrointestinal side effects. This is not only highly positive for NEX-22, but all other potential GLP-1/GIP formulations which make use of PharmaShell.

3 June, 2025

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Nanexa AB (publ) announced today that the company is entering an intensive period of international presence, with a particular focus on NEX-22 – the company’s long-acting formulation of liraglutide based on the PharmaShell® platform – featuring new data from its proprietary drug delivery technology.

6 May, 2025

Nanexa publishes interim report for January-March 2025

Download attachment

10 April, 2025

Nanexa publishes annual report for 2024

Download attachment